Genomic Vision Société Anonyme announces adjustments to its governance. Strengthening of the Executive Board: The Supervisory Board has duly noted the resignation of Mr. Aaron Bensimon as Chairman of the Management Board and has expressed its intention of strengthening the Company's sales momentum by appointing Mrs. Dominique Rémy-Renou as new Chairman of the Management Board (CEO). Mrs. Dominique Rémy-Renou will bring to Genomic Vision over 30 years of experience in the field of life sciences and genetics, where she has held various International Management positions at Applied Biosystems, Fluidigm Corporation and, more recently, Pacific Biosciences.

Dominique Rémy-Renou has always successfully contributed to developing sales, her expertise notably including sales, marketing, support, organization and, more broadly, managing people and operations. Mr. Pierre Schwich, previously Investment Director for 3i (Private Equity) and CFO of a number of high-growth listed technology companies, notably in the biotechnology sector (Cellectis, Pharnext), joined the management team of GENOMIC VISION as Chief Financial Officer earlier this year within the framework of the Company's new development prospects. Changes within the Supervisory Board: The Supervisory Board also wanted to adjust its organization in order to better meet the Company's requirements by limiting the number of its members while maintaining a very high level of expertise and highly complementary professional backgrounds and skills.

Mrs. Isabelle Racamier, Mrs. Elisabeth Jacobs and Mr. Florian Schödel have all stood down. Mrs. Elisabeth Ourliac, a member of the Supervisory Board since 2015, has been appointed President. Elisabeth Ourliac has brought substantial experience to Genomic Vision given her particularly rich and exemplary career at Airbus, of which she is currently Vice-President Strategy.

Her experience notably covers finance, audit and risk management, management of multicultural projects and strategy within an international high-tech environment. Mr. Stéphane Verdood, a member of the Supervisory Board since 2008, has been appointed Vice-President. Stéphane Verdood, a former consultant in the field of health and biotechnologies, is Managing Partner of Vesalius Biocapital, a longstanding investor in Genomic Vision.

Mrs. Tamar Saraga, a member of the Supervisory Board since 2015, has been appointed to the Audit Committee. Tamar Saraga has experience as a Chief Operating Officer and as a consultant in innovation and cross-border Mergers & Acquisitions for technological companies. The Supervisory Board of GENOMIC VISION now has three members, two women and a man, two of whom are independent.